Does the media refer more to COLL or TWST?

In the previous week, Twist Bioscience had 6 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 10 mentions for Twist Bioscience and 4 mentions for Collegium Pharmaceutical. Twist Bioscience's average media sentiment score of 0.96 beat Collegium Pharmaceutical's score of 0.47 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TVTX or COLL?

In the previous week, Travere Therapeutics had 11 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 15 mentions for Travere Therapeutics and 4 mentions for Collegium Pharmaceutical. Travere Therapeutics' average media sentiment score of 0.72 beat Collegium Pharmaceutical's score of 0.47 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ERAS or COLL?

In the previous week, Erasca had 4 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 8 mentions for Erasca and 4 mentions for Collegium Pharmaceutical. Erasca's average media sentiment score of 0.93 beat Collegium Pharmaceutical's score of 0.47 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, COLL or MANE?

Collegium Pharmaceutical has higher revenue and earnings than Veradermics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Collegium Pharmaceutical $780.57M 1.45 $62.87M $2.04 17.06 Veradermics N/A N/A N/A N/A N/A

Does the media favor COLL or MANE?

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 2 mentions for Veradermics. Collegium Pharmaceutical's average media sentiment score of 0.47 beat Veradermics' score of 0.05 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Collegium Pharmaceutical (COLL) Competitors

$34.80 +0.40 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$34.83 +0.03 (+0.09%)

As of 04:10 PM Eastern

Compare

COLL vs. TWST, TVTX, ERAS, MANE, and EWTX

Should you buy Collegium Pharmaceutical stock or one of its competitors? MarketBeat compares Collegium Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Collegium Pharmaceutical include Twist Bioscience (TWST), Travere Therapeutics (TVTX), Erasca (ERAS), Veradermics (MANE), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry.

How does Collegium Pharmaceutical compare to Twist Bioscience?

Collegium Pharmaceutical (NASDAQ:COLL) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Twist Bioscience had 6 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 10 mentions for Twist Bioscience and 4 mentions for Collegium Pharmaceutical. Twist Bioscience's average media sentiment score of 0.96 beat Collegium Pharmaceutical's score of 0.47 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.06
Twist Bioscience	$376.57M	11.21	-$77.67M	-$1.33	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to Twist Bioscience's net margin of -19.85%. Collegium Pharmaceutical's return on equity of 95.18% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Collegium Pharmaceutical has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Collegium Pharmaceutical presently has a consensus price target of $57.50, indicating a potential upside of 65.23%. Twist Bioscience has a consensus price target of $58.00, indicating a potential downside of 14.42%. Given Collegium Pharmaceutical's higher possible upside, research analysts clearly believe Collegium Pharmaceutical is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Collegium Pharmaceutical beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Collegium Pharmaceutical has a net margin of 9.41% compared to Travere Therapeutics' net margin of -4.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.86	-$25.55M	-$0.23	N/A
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.06

Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

In the previous week, Travere Therapeutics had 11 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 15 mentions for Travere Therapeutics and 4 mentions for Collegium Pharmaceutical. Travere Therapeutics' average media sentiment score of 0.72 beat Collegium Pharmaceutical's score of 0.47 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Travere Therapeutics currently has a consensus price target of $48.92, suggesting a potential upside of 4.66%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 65.23%. Given Collegium Pharmaceutical's higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Collegium Pharmaceutical beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Erasca?

Erasca (NASDAQ:ERAS) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Erasca has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

In the previous week, Erasca had 4 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 8 mentions for Erasca and 4 mentions for Collegium Pharmaceutical. Erasca's average media sentiment score of 0.93 beat Collegium Pharmaceutical's score of 0.47 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Collegium Pharmaceutical has a net margin of 9.41% compared to Erasca's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Erasca presently has a consensus target price of $20.11, suggesting a potential upside of 50.42%. Collegium Pharmaceutical has a consensus target price of $57.50, suggesting a potential upside of 65.23%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Collegium Pharmaceutical has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.06

Summary

Collegium Pharmaceutical beats Erasca on 10 of the 15 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Veradermics?

Collegium Pharmaceutical (NASDAQ:COLL) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Collegium Pharmaceutical has a net margin of 9.41% compared to Veradermics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Veradermics	N/A	N/A	N/A

Collegium Pharmaceutical has higher revenue and earnings than Veradermics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.06
Veradermics	N/A	N/A	N/A	N/A	N/A

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 2 mentions for Veradermics. Collegium Pharmaceutical's average media sentiment score of 0.47 beat Veradermics' score of 0.05 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical currently has a consensus target price of $57.50, indicating a potential upside of 65.23%. Veradermics has a consensus target price of $109.00, indicating a potential upside of 16.66%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Collegium Pharmaceutical is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Collegium Pharmaceutical beats Veradermics on 8 of the 9 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 4 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.47 beat Edgewise Therapeutics' score of -0.14 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a net margin of 9.41% compared to Edgewise Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Edgewise Therapeutics presently has a consensus price target of $44.22, suggesting a potential upside of 34.33%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 65.23%. Given Collegium Pharmaceutical's higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Collegium Pharmaceutical has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.06

Edgewise Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Edgewise Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.12B	$2.96B	$6.50B	$11.95B
Dividend Yield	N/A	1.77%	2.67%	5.61%
P/E Ratio	17.06	17.80	24.65	23.63
Price / Sales	1.45	289.23	500.87	105.21
Price / Cash	2.26	56.16	43.05	54.72
Price / Book	3.65	3.88	10.43	6.70
Net Income	$62.87M	$75.85M	$3.56B	$337.26M
7 Day Performance	12.04%	-1.87%	-1.39%	-1.41%
1 Month Performance	-7.94%	-6.20%	0.86%	1.15%
1 Year Performance	14.59%	12.60%	19.42%	22.61%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	3.0272 of 5 stars	$34.80 +1.2%	$57.50 +65.2%	+13.0%	$1.12B	$780.57M	17.06	210	Positive News
TWST Twist Bioscience	2.0319 of 5 stars	$70.04 +1.2%	$58.00 -17.2%	+110.0%	$4.31B	$376.57M	N/A	990
TVTX Travere Therapeutics	1.659 of 5 stars	$47.08 +2.8%	$48.92 +3.9%	+225.8%	$4.26B	$490.73M	N/A	460
ERAS Erasca	2.898 of 5 stars	$12.87 +7.5%	$20.11 +56.3%	+722.7%	$4.00B	N/A	N/A	120
MANE Veradermics	N/A	$90.74 -1.0%	$109.00 +20.1%	N/A	$3.83B	N/A	N/A	19	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. TWST, TVTX, ERAS, MANE, and EWTX

How does Collegium Pharmaceutical compare to Twist Bioscience?

Summary

How does Collegium Pharmaceutical compare to Travere Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Erasca?

Summary

How does Collegium Pharmaceutical compare to Veradermics?

Summary

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. TWST, TVTX, ERAS, MANE, and EWTX

How does Collegium Pharmaceutical compare to Twist Bioscience?

Does the media refer more to COLL or TWST?

Which has higher valuation and earnings, COLL or TWST?

Is COLL or TWST more profitable?

Which has more volatility and risk, COLL or TWST?

Do analysts prefer COLL or TWST?

Summary

How does Collegium Pharmaceutical compare to Travere Therapeutics?

Is TVTX or COLL more profitable?

Which has higher valuation & earnings, TVTX or COLL?

Which has more volatility & risk, TVTX or COLL?

Does the media favor TVTX or COLL?

Do analysts prefer TVTX or COLL?

Summary

How does Collegium Pharmaceutical compare to Erasca?

Which has more volatility & risk, ERAS or COLL?

Does the media prefer ERAS or COLL?

Do institutionals & insiders have more ownership in ERAS or COLL?

Is ERAS or COLL more profitable?

Do analysts rate ERAS or COLL?

Which has higher valuation & earnings, ERAS or COLL?

Summary

How does Collegium Pharmaceutical compare to Veradermics?

Is COLL or MANE more profitable?

Which has higher valuation and earnings, COLL or MANE?

Does the media favor COLL or MANE?

Do analysts recommend COLL or MANE?

Summary

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Does the media prefer EWTX or COLL?

Is EWTX or COLL more profitable?

Do analysts recommend EWTX or COLL?

Which has stronger valuation and earnings, EWTX or COLL?

Which has more volatility and risk, EWTX or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools